JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Intranasal Esketamine Reduces Depression and Suicidality, Modestly and Briefly

Joel Yager

Journal watch April 23, 2018 DOI: 10.1056/nejm-jw.na46536 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Peer reviewed
Topics	Depression Esketamine Ketamine

Abstract

Intravenous ketamine reduces symptoms of depression and suicidality for up to several weeks, but less is known about the non–FDA-approved intranasal

Explore topics

Depression Esketamine Ketamine

By condition and practice

Esketamine for depression Ketamine for depression